![Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy](https://www.cell.com/cms/attachment/5bce48f4-5d8b-4f4a-bcfb-b55f0b7a9a28/gr1_lrg.jpg)
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy
![Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3609e4eb-98ce-4f15-aead-bcd7844dad0e/gr1_lrg.jpg)
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews
![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/454940/454940_Thumb_400.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
![Hsieh Lab on Twitter: "Very interesting work from the @AsanganiLab in Ewing Sarcoma linking it's pathognomonic fusion protein with LOXHD1." / Twitter Hsieh Lab on Twitter: "Very interesting work from the @AsanganiLab in Ewing Sarcoma linking it's pathognomonic fusion protein with LOXHD1." / Twitter](https://pbs.twimg.com/media/Eu8DKVIU4AQrqic.png)
Hsieh Lab on Twitter: "Very interesting work from the @AsanganiLab in Ewing Sarcoma linking it's pathognomonic fusion protein with LOXHD1." / Twitter
![Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e001580/F1.large.jpg)
Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer
![Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fed8c7ab-63f7-4478-bc18-ce99956742dd/gr1.gif)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology
Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy
![Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years](https://www.spandidos-publications.com/article_images/ol/18/1/ol-18-01-0348-g00.jpg)
Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years
![Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review](https://assets.cureus.com/uploads/figure/file/246471/lightbox_c1747cb0f40611ebb741a9a1e985fb6f-Add-a-little-bit-of-body-text-12.png)
Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0ae1a419-8c04-4e6e-8a98-2b83b3eaa1d8/gr1.gif)